Francesco Bianchi Sells 1,800 Shares of LivaNova (NASDAQ:LIVN) Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director owned 7,228 shares of the company’s stock, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

LivaNova Price Performance

LivaNova stock traded down $1.52 during mid-day trading on Wednesday, hitting $73.90. 1,050,574 shares of the company were exchanged, compared to its average volume of 798,538. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The business has a fifty day moving average of $65.91 and a 200 day moving average of $63.88. LivaNova PLC has a 1-year low of $41.01 and a 1-year high of $75.82. The company has a market capitalization of $4.06 billion, a PE ratio of 37.90 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same period in the prior year, the company posted $0.88 earnings per share. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, sell-side analysts expect that LivaNova PLC will post 3.72 earnings per share for the current year.

Institutional Trading of LivaNova

Several large investors have recently made changes to their positions in LIVN. Artisan Partners Limited Partnership boosted its holdings in LivaNova by 94.5% in the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after acquiring an additional 1,179,436 shares during the last quarter. Wellington Management Group LLP increased its position in LivaNova by 83.5% in the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after purchasing an additional 1,067,349 shares during the period. Invesco Ltd. increased its position in LivaNova by 714.7% in the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after purchasing an additional 902,447 shares during the period. Scopia Capital Management LP acquired a new position in LivaNova during the 2nd quarter valued at about $36,657,000. Finally, Millennium Management LLC lifted its position in LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after purchasing an additional 544,033 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several research analyst reports. Piper Sandler restated an “overweight” rating and set a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Robert W. Baird decreased their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Mizuho increased their target price on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Barclays increased their target price on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, Stifel Nicolaus set a $80.00 target price on LivaNova in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $79.38.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.